GlassScriptPhysician profile
Alexander John Langley
NPI 1376961383
$1,984.43
in general payments reported to CMS, 2019-2025
23 companies · $637 in 2025
The $637 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $22.76 · 2021: $16.51 · 2023: $480 · 2024: $828 · 2025: $637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,945.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,945.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $453.19 | 2023-2025 | |
| Glaxosmithkline, LLC. | $188.71 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $185.74 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $169.46 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Merck Sharp & Dohme LLC | $140.62 | 2023-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.47 | 2023-2025 | Jardiance, Synjardy, Tradjenta |
| Astellas Pharma US INC | $121.26 | 2023-2024 | Veozah |
| Abbvie INC. | $103.49 | 2023-2025 | |
| Exact Sciences Corporation | $95.42 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $51.68 | 2024-2025 | Spravato |
| Shield Therapeutics INC | $43.26 | 2024 | |
| Idorsia Pharmaceuticals US INC | $37.78 | 2024 | Quviviq |
| Collegium Pharmaceutical, INC. | $35.74 | 2025 | Jornay Pm |
| Corium, LLC | $34.91 | 2023-2025 | Azstarys |
| Astrazeneca Pharmaceuticals LP | $33.23 | 2025 | Airsupra |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $24.29 | 2024 | Inspire |
| Amgen INC. | $23.38 | 2023 | Otezla, Repatha |
| Allergan, INC. | $22.76 | 2020 | |
| Phathom Pharmaceuticals, INC. | $22.02 | 2025 | Voquezna |
| Sanofi Pasteur INC. | $21.68 | 2023 | |
| Alkermes, INC. | $16.07 | 2024 | Vivitrol |
| Ibsa Pharma INC. | $15.51 | 2023 | Licart, Tirosint |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.76 | 2025 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Langley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.